This activity helps improve European and global health and the competitiveness of European health-related industries and businesses.
EU funding in 2012
€ 970.84 million
A pilot scheme for SMEs was implemented during 2012, receiving more than 15% of the total budget of the 2012 call. The first inducement prize on breakthrough innovations in vaccines was launched and expressions of interest have come from academia, SMEs and larger companies. These calls help advance the goals of Horizon 2020.
The Public-Private Partnership (PPP) Innovative Medicines Initiative (IMI) achieved results on drug toxicity, pain research and the genetic basis of autism. In 2012 the Commission drew up a legislative proposal for a new PPP under Horizon 2020 that would build on the current IMI. To meet this objective, the Commission launched an online public consultation and various other consultation forums. In addition, Member States that are participating in the European and Developing Countries Clinical Trials Partnership (EDCTP) published a business plan for the period 2014 to 2024.
In 2012 progress was also achieved in two existing Joint Programming Initiatives (JPIs). One was on neurodegenerative diseases and the other on anti-microbial resistance. Meanwhile, the research programmes of the contractual PPP, SEURAT-1, are now up and running. Its 2012 report has recently been published. To support the International Rare Diseases Research Consortium, 20 rare disease research projects were launched, with a €108 million EU contribution.
This activity generated a considerable number of scientific publications and much interest on the part of industry and SMEs. The EU's financial contribution increased from 12.7% to 17.3% and from 11.1% to 15.2% between 2011 and 2012 for the respective sectors.